ALMS

Alumis Inc.

Price Chart

Latest Quote

$19.27

-1.12 (-5.49%)

Current Price

Previous Close	$20.39
Open	$20.26
Day High	$21.00
Day Low	$19.07
Volume	1,034,042

Fetched: 2026-06-05T19:28:13

Stock Information

Shares Outstanding	123.43M
Total Debt	$35.66M
Cash Equivalents	$522.94M
Revenue	$8.40M
Net Income	$-237.42M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$2.43B
EPS (TTM)	$-1.78
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.94B
Sales	$8.40M
Income	$-237.42M
Book/sh	$4.46
Cash/sh	$4.24
Employees	225

Financial Ratios

Quick Ratio	7.41
Current Ratio	7.51
Debt/Eq	6.29

Returns & Margins

ROA	-58.79%
ROE	-64.57%
Gross Margin	100.00%
Operating Margin	-5652.44%

Ownership

Insider Ownership	0.64%
Institutional Ownership	99.78%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-6.45
P/S	289.22
P/B	4.28

Analyst Data

Recommendation	none
Target Price	$40.10

Technical Indicators

SMA20	$21.93
SMA50	$23.19
SMA200	$15.83
RSI	25.29
ATR	1.2014

Shares Float	85.87M
Short Float	15.85%
Short Ratio	10.79
Rel Volume	1.51

Performance History

Week	-11.76%
Month	-25.25%
Quarter	-29.14%
6 Months	+143.11%
YTD	+112.84%
Year	+458.94%
10 Years	+43.31%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-05	$19.06	1,436,500
2026-06-04	$20.39	729,500
2026-06-03	$20.08	1,154,500
2026-06-02	$20.04	1,510,800
2026-06-01	$20.33	1,643,400
2026-05-29	$21.60	1,024,600
2026-05-28	$21.40	437,000
2026-05-27	$21.33	822,200
2026-05-26	$22.33	666,300
2026-05-22	$22.02	567,300
2026-05-21	$22.17	874,100
2026-05-20	$22.04	761,800
2026-05-19	$21.52	1,335,600
2026-05-18	$21.15	1,281,100
2026-05-15	$22.87	943,700
2026-05-14	$24.63	507,100
2026-05-13	$24.86	841,700
2026-05-12	$23.51	602,400
2026-05-11	$23.66	962,700
2026-05-08	$23.66	977,300
2026-05-07	$23.76	923,900
2026-05-06	$25.50	560,500

About Alumis Inc.

Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.

📰 Latest News

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Insider Monkey • 2026-05-29T10:31:15Z

This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter

Motley Fool • 2026-05-24T14:33:59Z

Is Alumis (ALMS) Trading Short-Term Revenue for a Leaner, More Focused Business Model?

Simply Wall St. • 2026-05-20T04:34:25Z

Dyne Therapeutics Is Up 40%, but One Biotech Fund Just Disclosed Selling $14 Million Worth of Shares

Motley Fool • 2026-05-19T17:37:19Z

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Motley Fool • 2026-05-19T17:26:23Z

Dianthus Therapeutics Is Up 320% in a Year. One Major Investor Just Reduced Its Stake but Still Seems Bullish

Motley Fool • 2026-05-18T17:33:34Z

Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter

Motley Fool • 2026-05-17T18:33:40Z

Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back

Motley Fool • 2026-05-15T22:56:41Z

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Amid Oil Surge, Higher Yields, Geopolitical Uncertainty

MT Newswires • 2026-05-15T13:14:14Z

Biotech leaders campaign for Pazdur; Takeda to lay off 4,500 workers

BioPharma Dive • 2026-05-15T11:36:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$24,050,000	$0	$0	$0
Operating Revenue	$24,050,000	$0	$0	$0
Expenses
Total Expenses	$477,854,000	$300,754,000	$158,174,000	$113,850,000
Other Income Expense	$187,738,000	$-5,499,000	$-187,000	$-72,000
Other Non Operating Income Expenses	$-169,000	$-93,000	$-68,000	$-72,000
Net Non Operating Interest Income Expense	$14,180,000	$12,020,000	$3,368,000	$1,992,000
Operating Expense	$477,854,000	$300,754,000	$158,174,000	$113,850,000
General And Administrative Expense	$91,856,000	$35,200,000	$20,498,000	$12,546,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Net Interest Income	$14,180,000	$12,020,000	$3,368,000	$1,992,000
Interest Income	$14,180,000	$12,020,000	$3,368,000	$1,992,000
Normalized Income	$-424,843,162	$-288,827,000	$-154,874,000	$-111,930,000
Net Income From Continuing And Discontinued Operation	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Total Operating Income As Reported	$-453,804,000	$-300,754,000	$-158,174,000	$-113,850,000
Net Income Common Stockholders	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Net Income	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Net Income Including Noncontrolling Interests	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Net Income Continuous Operations	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Pretax Income	$-251,886,000	$-294,233,000	$-154,993,000	$-111,930,000
Special Income Charges	$187,907,000	$0	-	-
Interest Income Non Operating	$14,180,000	$12,020,000	$3,368,000	$1,992,000
Operating Income	$-453,804,000	$-300,754,000	$-158,174,000	$-113,850,000
Per Share
Diluted EPS	-	$-10.38	$-2.99	$-2.91
Basic EPS	-	$-10.38	$-2.99	$-2.91
Other
Tax Effect Of Unusual Items	$6,388,838	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-638,215,000	$-292,196,000	$-156,771,000	$-113,600,000
Total Unusual Items	$187,907,000	$-5,406,000	$-119,000	-
Total Unusual Items Excluding Goodwill	$187,907,000	$-5,406,000	$-119,000	-
Reconciled Depreciation	$3,496,000	$3,152,000	$1,284,000	$250,000
EBITDA (Bullshit earnings)	$-450,308,000	$-297,602,000	$-156,890,000	$-113,600,000
EBIT	$-453,804,000	$-300,754,000	$-158,174,000	$-113,850,000
Diluted NI Availto Com Stockholders	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Tax Provision	$-8,561,000	$0	-	-
Restructuring And Mergern Acquisition	$-187,907,000	$0	-	-
Research And Development	$385,998,000	$265,554,000	$137,676,000	$101,304,000
Selling General And Administration	$91,856,000	$35,200,000	$20,498,000	$12,546,000
Other Gand A	$91,856,000	$35,200,000	$20,498,000	$12,546,000
Diluted Average Shares	-	$28,341,866	$51,844,729	$38,410,615
Basic Average Shares	-	$28,341,866	$51,844,729	$38,410,615
Gain On Sale Of Security	-	$-5,406,000	$-119,000	-

Fetched: 2026-05-30

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$250,338,000	$260,104,000	$-339,260,000	$-195,242,000
Total Assets	$411,940,000	$340,992,000	$89,612,000	$108,168,000
Total Non Current Assets	$93,708,000	$34,804,000	$36,255,000	$5,613,000
Other Non Current Assets	$7,588,000	$1,113,000	$1,031,000	$1,138,000
Goodwill And Other Intangible Assets	$50,959,000	$0	-	-
Current Assets	$318,232,000	$306,188,000	$53,357,000	$102,555,000
Other Current Assets	$1,142,000	$762,000	$95,000	-
Restricted Cash	$82,000	$0	$113,000	$206,000
Prepaid Assets	$6,424,000	$15,351,000	$3,475,000	$8,984,000
Receivables	$2,083,000	$1,812,000	$722,000	$500,000
Taxes Receivable	$740,000	$1,114,000	$614,000	$500,000
Accrued Interest Receivable	$1,343,000	$698,000	$108,000	-
Cash Cash Equivalents And Short Term Investments	$308,501,000	$288,263,000	$48,952,000	$92,865,000
Cash And Cash Equivalents	$89,670,000	$169,526,000	$45,996,000	$25,610,000
Debt
Total Debt	$36,914,000	$30,722,000	$32,580,000	$1,779,000
Long Term Debt And Capital Lease Obligation	$32,244,000	$29,165,000	$30,860,000	$469,000
Current Debt And Capital Lease Obligation	$4,670,000	$1,557,000	$1,720,000	$1,310,000
Liabilities
Total Liabilities Net Minority Interest	$110,643,000	$80,888,000	$428,872,000	$303,410,000
Total Non Current Liabilities Net Minority Interest	$37,325,000	$29,978,000	$408,001,000	$290,058,000
Other Non Current Liabilities	$330,000	$813,000	$1,771,000	$4,116,000
Non Current Deferred Liabilities	$4,751,000	$0	-	-
Non Current Deferred Taxes Liabilities	$2,140,000	$0	-	-
Current Liabilities	$73,318,000	$50,910,000	$20,871,000	$13,352,000
Current Deferred Liabilities	$1,458,000	$0	-	-
Payables And Accrued Expenses	$66,946,000	$49,353,000	$19,151,000	$12,042,000
Payables	$10,106,000	$9,624,000	$1,118,000	$1,720,000
Accounts Payable	$10,106,000	$9,624,000	$1,118,000	$1,720,000
Equity
Common Stock Equity	$301,297,000	$260,104,000	$-339,260,000	$-195,242,000
Total Equity Gross Minority Interest	$301,297,000	$260,104,000	$-339,260,000	$-195,242,000
Stockholders Equity	$301,297,000	$260,104,000	$-339,260,000	$-195,242,000
Gains Losses Not Affecting Retained Earnings	$188,000	$40,000	$2,000	$-127,000
Other Equity Adjustments	$188,000	$40,000	$2,000	$-127,000
Retained Earnings	$-901,876,000	$-658,551,000	$-364,318,000	$-209,325,000
Preferred Securities Outside Stock Equity	-	$0	$375,370,000	$285,473,000
Other
Ordinary Shares Number	$104,706,773	$54,407,327	$51,844,729	$51,844,729
Share Issued	$104,706,773	$54,407,327	$51,844,729	$51,844,729
Tangible Book Value	$250,338,000	$260,104,000	$-339,260,000	$-195,242,000
Invested Capital	$301,297,000	$260,104,000	$-339,260,000	$-195,242,000
Working Capital	$244,914,000	$255,278,000	$32,486,000	$89,203,000
Capital Lease Obligations	$36,914,000	$30,722,000	$32,580,000	$1,779,000
Total Capitalization	$301,297,000	$260,104,000	$-339,260,000	$-195,242,000
Additional Paid In Capital	$1,202,975,000	$918,610,000	$25,055,000	$14,209,000
Capital Stock	$10,000	$5,000	$1,000	$1,000
Common Stock	$10,000	$5,000	$1,000	$1,000
Preferred Stock	$0	$0	$0	-
Non Current Deferred Revenue	$2,611,000	$0	-	-
Long Term Capital Lease Obligation	$32,244,000	$29,165,000	$30,860,000	$469,000
Current Deferred Revenue	$1,458,000	$0	-	-
Current Capital Lease Obligation	$4,670,000	$1,557,000	$1,720,000	$1,310,000
Pensionand Other Post Retirement Benefit Plans Current	$244,000	$0	$5,585,000	$3,576,000
Current Accrued Expenses	$56,840,000	$39,729,000	$18,033,000	$10,322,000
Net PPE	$35,161,000	$33,691,000	$35,224,000	$4,475,000
Accumulated Depreciation	$-7,988,000	$-4,557,000	$-1,408,000	$-257,000
Gross PPE	$43,149,000	$38,248,000	$36,632,000	$4,732,000
Leases	$17,655,000	$17,618,000	$17,592,000	$31,000
Other Properties	$22,814,000	$17,950,000	$16,360,000	$3,594,000
Machinery Furniture Equipment	$2,680,000	$2,680,000	$2,680,000	$529,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$218,831,000	$118,737,000	$2,956,000	$67,255,000
Construction In Progress	-	-	$0	$578,000

Fetched: 2026-05-30

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-370,176,000	$-256,810,000	$-134,474,000	$-110,128,000
Operating Activities
Operating Cash Flow	$-369,523,000	$-255,078,000	$-129,975,000	$-107,722,000
Cash Flow From Continuing Operating Activities	$-369,523,000	$-255,078,000	$-129,975,000	$-107,722,000
Operating Gains Losses	-	$5,411,000	$1,030,000	-
Investing Activities
Capital Expenditure	$-653,000	$-1,732,000	$-4,499,000	$-2,406,000
Investing Cash Flow	$287,877,000	$-113,790,000	$60,472,000	$-68,751,000
Cash Flow From Continuing Investing Activities	$287,877,000	$-113,790,000	$60,472,000	$-68,751,000
Net Other Investing Changes	$49,742,000	-	-	-
Financing Activities
Issuance Of Capital Stock	$0	$451,777,000	$89,778,000	$99,893,000
Financing Cash Flow	$2,067,000	$492,367,000	$89,682,000	$101,627,000
Cash Flow From Continuing Financing Activities	$2,067,000	$492,367,000	$89,682,000	$101,627,000
Net Preferred Stock Issuance	$0	$258,461,000	$89,778,000	$99,893,000
Preferred Stock Issuance	$0	$258,461,000	$89,778,000	$99,893,000
Net Common Stock Issuance	$0	$193,316,000	$0	-
Common Stock Issuance	$0	$193,316,000	-	-
Net Other Financing Charges	-	$40,000,000	$-485,000	-
Repurchase Of Capital Stock	-	-	$0	-
Other
End Cash Position	$91,053,000	$170,632,000	$47,133,000	$26,954,000
Beginning Cash Position	$170,632,000	$47,133,000	$26,954,000	$101,800,000
Changes In Cash	$-79,579,000	$123,499,000	$20,179,000	$-74,846,000
Proceeds From Stock Option Exercised	$2,067,000	$590,000	$389,000	$1,734,000
Net Investment Purchase And Sale	$238,788,000	$-112,058,000	$64,971,000	$-66,345,000
Sale Of Investment	$447,955,000	$128,000,000	$76,250,000	$142,730,000
Purchase Of Investment	$-209,167,000	$-240,058,000	$-11,279,000	$-209,075,000
Net PPE Purchase And Sale	$-653,000	$-1,732,000	$-4,499,000	$-2,406,000
Purchase Of PPE	$-653,000	$-1,732,000	$-4,499,000	$-2,406,000
Change In Working Capital	$17,757,000	$14,760,000	$12,058,000	$-1,916,000
Change In Other Working Capital	$4,069,000	-	-	-
Change In Other Current Liabilities	$-3,005,000	$-1,858,000	$-144,000	$-820,000
Change In Other Current Assets	$-5,535,000	$0	-	-
Change In Payables And Accrued Expense	$-6,474,000	$30,251,000	$7,016,000	$7,257,000
Change In Accrued Expense	$8,123,000	$21,745,000	$7,658,000	$5,963,000
Change In Payable	$-14,597,000	$8,506,000	$-642,000	$1,294,000
Change In Account Payable	$-6,036,000	$8,506,000	$-642,000	$1,294,000
Change In Tax Payable	$-8,561,000	$0	-	-
Change In Income Tax Payable	$-8,561,000	$0	-	-
Change In Prepaid Assets	$28,702,000	$-13,633,000	$5,186,000	$-8,353,000
Other Non Cash Items	$-186,206,000	$60,000	$2,010,000	$950,000
Stock Based Compensation	$43,524,000	$19,457,000	$8,625,000	$5,960,000
Asset Impairment Charge	$529,000	$0	$555,000	$0
Amortization Of Securities	$-5,298,000	$-3,685,000	$-544,000	$-1,036,000
Depreciation Amortization Depletion	$3,496,000	$3,152,000	$1,284,000	$250,000
Depreciation And Amortization	$3,496,000	$3,152,000	$1,284,000	$250,000
Gain Loss On Sale Of PPE	$0	$5,000	$911,000	$0
Net Income From Continuing Operations	$-243,325,000	$-294,233,000	$-154,993,000	$-111,930,000
Gain Loss On Investment Securities	-	$5,406,000	$119,000	-
Common Stock Payments	-	-	$0	-

Fetched: 2026-05-30